Author:
Shin Jaeseung,Lim Joon Seok,Huh Yong-Min,Kim Jie-Hyun,Hyung Woo Jin,Chung Jae-Joon,Han Kyunghwa,Kim Sungwon
Abstract
AbstractThis study aims to evaluate the performance of a radiomic signature-based model for predicting recurrence-free survival (RFS) of locally advanced gastric cancer (LAGC) using preoperative contrast-enhanced CT. This retrospective study included a training cohort (349 patients) and an external validation cohort (61 patients) who underwent curative resection for LAGC in 2010 without neoadjuvant therapies. Available preoperative clinical factors, including conventional CT staging and endoscopic data, and 438 radiomic features from the preoperative CT were obtained. To predict RFS, a radiomic model was developed using penalized Cox regression with the least absolute shrinkage and selection operator with ten-fold cross-validation. Internal and external validations were performed using a bootstrapping method. With the final 410 patients (58.2 ± 13.0 years-old; 268 female), the radiomic model consisted of seven selected features. In both of the internal and the external validation, the integrated area under the receiver operating characteristic curve values of both the radiomic model (0.714, P < 0.001 [internal validation]; 0.652, P = 0.010 [external validation]) and the merged model (0.719, P < 0.001; 0.651, P = 0.014) were significantly higher than those of the clinical model (0.616; 0.594). The radiomics-based model on preoperative CT images may improve RFS prediction and high-risk stratification in the preoperative setting of LAGC.
Funder
the National Research Foundation of Korea funded by the Ministry of Education
Publisher
Springer Science and Business Media LLC
Reference39 articles.
1. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA: A Cancer J. Clin. 66, 7–30 (2016).
2. Torre, L. A. et al. Global cancer statistics, 2012. CA: A Cancer J. Clin. 65, 87–108 (2015).
3. Choi, A. H., Kim, J. & Chao, J. Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond. WJG 21, 7343–7348 (2015).
4. Lee, J. et al. Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer With D2 lymph node dissection: The ARTIST Trial. J. Clin. Oncol. 30, 268–273 (2012).
5. Bang, Y. J. et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): A phase 3 open-label, randomised controlled trial. Lancet (London, England) 379, 315–321 (2012).